Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Leases (2019 - 2025)

CytomX Therapeutics' Current Leases history spans 7 years, with the latest figure at $4.2 million for Q4 2025.

  • For Q4 2025, Current Leases fell 17.59% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, down 17.59%, while the annual FY2025 figure was $4.2 million, 17.59% down from the prior year.
  • Current Leases reached $4.2 million in Q4 2025 per CTMX's latest filing, down from $5.6 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $5.6 million in Q3 2025 to a low of $3.6 million in Q4 2021.
  • Average Current Leases over 5 years is $4.5 million, with a median of $4.5 million recorded in 2023.
  • Peak YoY movement for Current Leases: grew 12.82% in 2022, then decreased 17.59% in 2025.
  • A 5-year view of Current Leases shows it stood at $3.6 million in 2021, then increased by 12.82% to $4.1 million in 2022, then grew by 12.42% to $4.6 million in 2023, then rose by 12.12% to $5.1 million in 2024, then decreased by 17.59% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Current Leases are $4.2 million (Q4 2025), $5.6 million (Q3 2025), and $5.4 million (Q2 2025).